Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 10Recruiting 5Unknown 3Active not recruiting 3Terminated 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 1

Conditions

Tuberous Sclerosis 2 1Tuberous Sclerosis 1 1Tuberous Sclerosis 1Spasms, Infantile 1Seizures 1Lennox Gastaut Syndrome 1Glioblastoma 1Epilepsy 1Epilepsies, Myoclonic 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Cannabidiol × Clear all
NCT05753007 2026-03-16

A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients

Mclean Hospital

Phase 2 Terminated
2 enrolled 13 charts
CNS

Glioblastoma

NCT04485104 2025-10-31

Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

Jazz Pharmaceuticals

Phase 3 Terminated
3 enrolled 28 charts

Tuberous Sclerosis 1, Tuberous Sclerosis 2, Epilepsy, Epilepsies, Myoclonic, Seizures, Spasms, Infantile, Tuberous Sclerosis, Lennox Gastaut Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡